Ibogaine for Methadone Addiction: The Switch, the Evidence and the Risks

Ibogaine can be used by people who want to come off methadone, but methadone changes the plan more than any other opioid. Every published hospital protocol switched patients from methadone to a short-acting opioid such as morphine before giving ibogaine, because both drugs affect heart rhythm and methadone lingers for days. That switch, the cardiac screening, and a plan for the weeks after treatment matter as much as the ibogaine itself.

This guide covers why methadone is different, what the switch involves, what the research on ibogaine for opioid dependence actually shows, the heart risks, and the risks of leaving methadone at all. Psychedelic Connect is a patient advisory service; we help people find medically supervised ibogaine clinics outside the US. Call (866) 435-7057 to talk it through.

Why Methadone Is Different From Heroin or Fentanyl

Methadone is a synthetic, full mu-opioid agonist, and it has been used to treat opioid addiction in the US since 1947 (NIDA). It works because it activates opioid receptors slowly and for a long time, which prevents withdrawal and craving with one daily dose.

That long action is what makes it harder to come off. The FDA label puts methadone’s terminal half-life at 8 to 59 hours, and notes that it can persist in the liver and other tissues. Compared with morphine withdrawal, methadone withdrawal starts more slowly, lasts longer and is usually less severe. When 27 patients on about 60 mg a day were switched to morphine over one week, 91% of their methadone had cleared, the average half-life was 59 hours, withdrawal peaked 12 to 24 hours after the switch, and 24 of the 27 needed more morphine than planned (Glue et al., 2016).

If you taper methadone with your own prescriber, the FDA label advises steps of generally less than 10% of the dose, 10 to 14 days apart, and warns of a high risk of relapse after stopping. Never stop methadone abruptly.

Before You Leave Methadone: The Risk Nobody Should Skip

Methadone is one of the best-evidenced treatments in addiction medicine. In randomised trials, it kept people in treatment and cut heroin use compared with non-medication approaches (Cochrane review). Across cohort studies of 122,885 people, death rates were about three times lower while people were in methadone treatment than after they left it (Sordo et al., BMJ 2017):

Addiction specialists have warned that coming off methadone or buprenorphine to try an unproven treatment could raise overdose risk for some people, and that ibogaine is better framed as a complement to medication for opioid use disorder than as its opponent (Terasaki et al.). We agree. If methadone is working for you, that is a good outcome. Ibogaine is for people who have decided, with their doctor, that they want to stop, and who will plan for relapse: naloxone on hand, aftercare booked, and the option to restart medication if needed.

The Switch: Why Methadone Must Clear Before Ibogaine

Clinics do not give ibogaine to someone with methadone still active in their system, for two reasons set out in the Global Ibogaine Therapy Alliance’s clinical guidelines:

• Heart rhythm. Methadone itself prolongs the QT interval, and so does ibogaine. Combining them stacks the risk.
• Opioid effects. Ibogaine can strengthen the effect of opioids still present, risking overdose, followed by a prolonged withdrawal as they wear off.

So the usual approach is to move from methadone to a short-acting opioid, such as morphine, and wait for the methadone to clear. The GITA guidelines aim for residual methadone of no more than about 2 mg, which they estimate at roughly 7 days on the short-acting opioid if you assume a 24-hour half-life, or 14 days or more with a 48-hour half-life. Both hospital studies of ibogaine or noribogaine in people on opioid maintenance switched patients to morphine about a week beforehand, and the largest case series switched opioid patients to oral morphine on arrival (Mash et al., 2018).

How long your switch takes depends on your dose, your metabolism and the clinic’s protocol. It is planned with your prescriber and the treating clinic, supervised, and never done on your own. Expect some withdrawal discomfort during the switch; this is one reason a residential stay matters.

What the Research on Ibogaine for Opioid Dependence Shows

There are no randomised controlled trials of ibogaine for opioid use disorder. A 2025 systematic review found five ibogaine studies with 166 participants in total (Piper et al.). What exists is observational:

• Brown & Alper, 2017 (n=30, heroin and/or oxycodone): withdrawal scores fell from 31 to 14 about 76 hours after treatment, and 15 of 30 reported no opioid use in the 30 days before their one-month follow-up. No control group (source).
• Noller et al., 2018 (n=14, New Zealand, where ibogaine is legally available): drug-use scores fell significantly at 12 months, though only 8 completed every interview. One enrolled patient died during treatment (source).
• Malcolm et al., 2018 (n=50, a clinic in Tijuana, retrospective): 48 hours after ibogaine, 78% had no objective withdrawal signs and 79% reported minimal craving (source).
• Mash et al., 2018 (n=191, 102 of them opioid-dependent, St Kitts): reduced withdrawal and craving; patients with slow heart rate or long QT were excluded (source).

These studies mostly enrolled people using heroin or oxycodone, not methadone specifically. They show that ibogaine can sharply reduce acute withdrawal and craving. They cannot tell you how ibogaine compares with staying on methadone, because no study has tested that. How ibogaine works is still not settled; researchers describe it as acting on many systems at once, including NMDA, opioid, sigma-2 and serotonin receptors, through ibogaine and its long-lasting metabolite noribogaine (Ona et al., 2023).

Heart Safety: The Main Medical Risk

The most detailed safety data comes from a Dutch hospital study of 14 people on opioid maintenance who were switched to morphine and then given a single 10 mg/kg dose of ibogaine (Knuijver et al., 2021). Their QTc rose by an average of 95 ms (range 29 to 146), half passed 500 ms, and in 6 of the 14 it stayed above 450 ms for more than 24 hours. Every patient had severe temporary loss of coordination. No dangerous arrhythmia occurred, but the study was run with continuous hospital monitoring.

Outside such settings, deaths have been reported. A forensic review of 19 deaths within 76 hours of taking ibogaine found pre-existing heart disease and/or other drugs explained or contributed to 12 of the 14 cases with adequate post-mortem data (Alper et al., 2012). This is why an ECG, bloodwork, a full medication review and continuous cardiac monitoring are non-negotiable. See our ibogaine safety guide for the full screening standard.

Methadone vs Ibogaine at a Glance

Is Ibogaine Legal?

Not in the United States. Ibogaine is a Schedule I controlled substance (21 CFR 1308.11) and is not FDA-approved. An executive order signed on 18 April 2026 directs the FDA and DEA to create a Right to Try pathway that includes ibogaine compounds, and in April 2026 the FDA cleared an early-phase US study of noribogaine for alcohol use disorder (FDA). Texas SB 2308 (2025) set up a consortium to run FDA trials of ibogaine for opioid use disorder. None of this makes ibogaine treatment available in the US today, and ibogaine does not hold FDA Breakthrough Therapy designation. Patients travel to medically supervised clinics in Mexico and a few other countries.

Who May Be a Candidate, and Who Is Not

You may be a candidate if you have decided with your doctor that you want to stop methadone, you are medically stable, and you can commit to the switch, a residential stay and aftercare.

Ibogaine is usually ruled out by a prolonged QTc or other heart disease, significant liver disease, a history of psychosis or mania, and medications that prolong QT or interact through the liver enzyme CYP2D6. Benzodiazepine or alcohol dependence must be treated first, because withdrawal seizures were a factor in reported deaths. A clinic that does not ask for an ECG, bloodwork and your full medication list is one to avoid; our guide on how to choose an ibogaine clinic covers the other red flags.

What It Costs

Programs at the clinics we work with generally run $5,000–$15,000 depending on length of stay, facility and whether medical detox is needed. Programs that include opioid detox, which methadone patients need, start at around $8,500. The lower end applies only to people with no current opioid use. See the full cost breakdown.

Frequently Asked Questions: Ibogaine for Methadone

Can you take ibogaine while on methadone?

No. Published clinical protocols do not give ibogaine to people with methadone in their system. Hospital studies switched patients to short-acting morphine first, because methadone also prolongs the QT interval and ibogaine can strengthen opioid effects.

How long do you have to be off methadone before ibogaine?

There is no FDA-endorsed standard. Practitioner guidelines aim for residual methadone of about 2 mg or less, roughly 7 to 14 or more days on a short-acting opioid depending on how fast you clear it. In one research switch, methadone’s average half-life was 59 hours and 91% had cleared after a week. The clinic sets your timeline.

Is ibogaine better than methadone for opioid addiction?

No study has compared them head to head. Methadone is backed by randomised trials showing better retention and less heroin use, and staying on it is linked with about three times lower death rates. Ibogaine evidence comes from small observational studies that show reduced withdrawal and craving.

Is it risky to stop methadone to try ibogaine?

It can be. Death rates rise in the weeks after leaving methadone treatment, and addiction specialists warn that stopping it for an unproven therapy may raise overdose risk. Any transition should be medically supervised, with naloxone on hand and aftercare in place.

Is ibogaine dangerous for your heart?

It carries real cardiac risk. In a Dutch hospital study, QTc rose by an average of 95 ms and half of patients passed 500 ms, and deaths linked to ibogaine have been reported, often with heart disease or other drugs involved. That is why ECG screening and continuous monitoring are essential.

How much does ibogaine treatment for methadone addiction cost?

Generally $5,000–$15,000 depending on stay, facility and detox needs; programs that include opioid detox start at around $8,500. For comparison, NIDA cited about $126 a week for methadone in a US program (a c. 2016 estimate).

Can I go back on methadone if ibogaine does not work?

Yes. Ibogaine does not prevent future medication treatment. If you return to opioid use, restarting methadone or buprenorphine remains an option, and lost tolerance makes it urgent to get back into care rather than use at old doses.

Talk It Through First

Coming off methadone is a serious medical decision, and the right answer is not the same for everyone. We can help you understand whether ibogaine fits your history, what the switch would involve, and which medically supervised clinics handle long-acting opioids. Call (866) 435-7057 or book a consultation. If you need help now, the SAMHSA National Helpline (1-800-662-4357) is free, confidential and open 24/7.

Psychedelic Connect is a treatment advisory service and does not provide medical advice. Always make decisions about methadone with your prescriber.